European CHMP recommends extending indication of brigatinib to include patients not previously treated with an anaplastic lymphoma kinase (ALK) inhibitor

The CHMP has recommended approval of brigatinib for the treatment of adults with ALK-positive advanced non-small cell lung cancer who have not received previous treatment with an ALK inhibitor. It is currently only approved for use in patients previously treated with crizotinib.


European Medicines Agency